Main content

    Colorectal Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer
    Description: This study is to examine if Nivolumab alone or in combination with Ipilimumab will demonstrate a meaningful objective response rate in patients with recurrent and metastatic colon cancer who also have a specific biomarker in their tumors
    Investigators: Ari Baron, MD
    Eligibility: Male & female subjects, 18 y/o and older, with histologically confirmed colorectal cancer
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study BMS CA209-142

    Title: A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
    Description: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
    Investigators: NCI - National Cancer Institute
    Eligibility: Subjects with colon cancer without rectal cancer
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study CALGB 80702

    Title: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac-PACES
    Description: The study is to evaluate the effectiveness of the combination of eflornithine and sulindac in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer
    Investigators: NCI - National Cancer Institute
    Eligibility: Male & female subjects, 18 y/o and older, with a history of Stage 0-III colon cancer with primary resection 1 year previously. Patients with rectosigmoid cancers are eligible if no RT administered
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study SWOG S0820

    • updated October 2014

    Back to top